Generation of a novel fully human non-superagonistic anti-CD28 antibody with efficient and safe T-cell co-stimulation properties

Antibody-based therapeutics represent an important class of biopharmaceuticals in cancer immunotherapy. CD3 bispecific T-cell engagers activate cytotoxic T-cells and have shown remarkable clinical outcomes against several hematological malignancies. The absence of a costimulatory signal through CD28...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Abdullah Elsayed, Christian Pellegrino, Louis Plüss, Frederik Peissert, Ramon Benz, Franziska Ulrich, Gudrun Thorhallsdottir, Sheila Dakhel Plaza, Alessandra Villa, Jacqueline Mock, Emanuele Puca, Roberto De Luca, Markus G. Manz, Cornelia Halin, Dario Neri
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Taylor & Francis Group 2023-12-01
Serie:	mAbs
Soggetti:	bispecific antibodies cancer immunotherapy CD28 CD3 monoclonal antibodies phage display technology
Accesso online:	https://www.tandfonline.com/doi/10.1080/19420862.2023.2220839
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!